Publications by authors named "A Ekbom"
Background: Myotonic dystrophy type 1 (DM1) is a monogenetic disease affecting many organs. Gastrointestinal symptoms are prevalent and of considerable consequences for affected individuals. The life expectancy is shortened and the objective of the study is to evaluate if gastrointestinal symptoms can predict the outcome of the disease.
View Article and Find Full Text PDFBackground: We determined the impact of an increased two-stool faecal immunochemical test (FIT) cut-off on colonoscopy positivity and relative sensitivity and specificity in the randomized controlled screening trial screening of Swedish colons conducted in Sweden.
Methods: We performed a cross-sectional analysis of participants in the FIT arm that performed FIT between March 2014 and 2020 within the study registered with ClinicalTrials.gov, NCT02078804, who had a faecal haemoglobin concentration of at least 10 µg/g in at least one of two stool samples and who underwent a colonoscopy (n = 3841).
Background: Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk.
Objectives: To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT.
Methods: We developed a cohort study using Swedish national registers 2013-2019.
Background: It is well documented that smokers suffer increased risk of postoperative complications after medical surgery, for example delayed healing and increased risk of infection. It is also known that preoperative smoking cessation can reduce the risk of these complications. Because of this there are guidelines regarding preoperative smoking cessation in non-oral medical surgery.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the effectiveness of rivaroxaban compared to low-molecular-weight heparins (LMWHs) in treating cancer-associated venous thromboembolism (CT) among patients not at high risk of bleeding.
- Researchers analyzed data from over 2,200 patients, monitoring them for 12 months and finding no significant difference in the rates of VTE recurrences, major bleeding, and overall mortality between the two treatment groups.
- The findings suggest that rivaroxaban is a safe and effective alternative to LMWH for treating CT, reinforcing existing treatment guidelines.